Last reviewed · How we verify
Synera patch twice daily
Synera patch, marketed by International Clinical Research Institute, is administered twice daily and holds a niche position in the pharmaceutical market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk is the lack of clear primary indication and revenue data, which may limit its commercial potential and strategic planning.
At a glance
| Generic name | Synera patch twice daily |
|---|---|
| Sponsor | International Clinical Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow (PHASE4)
- Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy (PHASE2)
- Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synera patch twice daily CI brief — competitive landscape report
- Synera patch twice daily updates RSS · CI watch RSS
- International Clinical Research Institute portfolio CI